Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start
Article first published online: 31 OCT 2013
© 2013 British HIV Association
How to Cite
Angeletti, C., Pezzotti, P., Antinori, A., Mammone, A., Navarra, A., Orchi, N., Lorenzini, P., Mecozzi, A., Ammassari, A., Murachelli, S., Ippolito, G. and Girardi, E. (2013), Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Medicine. doi: 10.1111/hiv.12097
- Article first published online: 31 OCT 2013
- Manuscript Accepted: 2 SEP 2013
- AIDS Project of the Italian Ministry of Health. Grant Number: 40H79
- Ricerca Corrente INMI Spallanzani
- Gilead Sciences
- antiretroviral therapy;
- health care costs;
- HIV infection;
- mathematical model;
- treatment guidelines
Combination antiretroviral therapy (cART) has become the main driver of total costs of caring for persons living with HIV (PLHIV). The present study estimated the short/medium-term cost trends in response to the recent evolution of national guidelines and regional therapeutic protocols for cART in Italy.
We developed a deterministic mathematical model that was calibrated using epidemic data for Lazio, a region located in central Italy with about six million inhabitants.
In the Base Case Scenario, the estimated number of PLHIV in the Lazio region increased over the period 2012–2016 from 14 414 to 17 179. Over the same period, the average projected annual cost for treating the HIV-infected population was €147.0 million. An earlier cART initiation resulted in a rise of 2.3% in the average estimated annual cost, whereas an increase from 27% to 50% in the proportion of naïve subjects starting cART with a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen resulted in a reduction of 0.3%. Simplification strategies based on NNRTIs co-formulated in a single tablet regimen and protease inhibitor/ritonavir-boosted monotherapy produced an overall reduction in average annual costs of 1.5%. A further average saving of 3.3% resulted from the introduction of generic antiretroviral drugs.
In the medium term, cost saving interventions could finance the increase in costs resulting from the inertial growth in the number of patients requiring treatment and from the earlier treatment initiation recommended in recent guidelines.